NASDAQ:ENTA Enanta Pharmaceuticals Q2 2026 Earnings Results & Report $11.47 +0.29 (+2.59%) Closing price 10/15/2026 04:00 PM EasternExtended Trading$11.46 -0.01 (-0.09%) As of 10/15/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Enanta Pharmaceuticals beat analyst expectations on both earnings and revenue in its Q2 2026 results, released May 11, 2026. The company reported EPS of -$0.45 versus the -$0.46 consensus estimate, while revenue of $17.16 million topped the $17.03 million estimate by $0.13 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateMay 11, 2026TimeBefore Market OpensConference Call4:00 PM ET Enanta Pharmaceuticals EPS ResultsActual EPS-$0.45Consensus EPS -$0.46Beat/MissBeat by +$0.01One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersEnanta Pharmaceuticals Revenue ResultsActual Revenue$17.16 millionExpected Revenue$17.03 millionBeat/MissBeat by +$132.00 thousandYoY Revenue GrowthN/AUpcoming EarningsEnanta Pharmaceuticals' Q4 2026 earnings is estimated for Monday, November 16, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Enanta Pharmaceuticals Q2 2026 Earnings FAQ Did Enanta Pharmaceuticals beat earnings estimates for Q2 2026? Enanta Pharmaceuticals (NASDAQ:ENTA) reported earnings of -$0.45 per share for Q2 2026, beating the consensus estimate of -$0.46. The report was announced on Monday, May 11, 2026. What was Enanta Pharmaceuticals' revenue for Q2 2026? Enanta Pharmaceuticals reported revenue of $17.16 million for Q2 2026, against a consensus estimate of $17.03 million. When is Enanta Pharmaceuticals' next earnings date? Enanta Pharmaceuticals' next earnings date is estimated for Monday, November 16, 2026. MarketBeat tracks confirmed and estimated earnings dates for Enanta Pharmaceuticals on the company's earnings history page. Enanta Pharmaceuticals Earnings HeadlinesEnanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026October 13 at 8:04 AM | marketscreener.comMEnanta Pharmaceuticals (NASDAQ:ENTA) Stock Rating Lowered by Wall Street ZenOctober 11, 2026 | americanbankingnews.comStop picking AI winners. Start collecting every ThursdayOne fund holds Nvidia, CrowdStrike, Palantir and other major AI names, and pays a 34% annualized distribution rate. Instead of guessing which AI stock wins, this fund delivers income every single Thursday, up to $1,051 a month. Chief Income Strategist Tim Plaehn breaks down what's inside the fund and how the weekly payouts work.October 16 at 1:00 AM | Investors Alley (Ad)Head-To-Head Survey: Enanta Pharmaceuticals (NASDAQ:ENTA) vs. Amphastar Pharmaceuticals (NASDAQ:AMPH)October 6, 2026 | americanbankingnews.comEnanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026August 10, 2026 | businesswire.comEnanta Faces Patent Setback in Paxlovid LitigationJune 23, 2026 | tipranks.comSee More Enanta Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Enanta Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enanta Pharmaceuticals and other key companies, straight to your email. Email Address About Enanta PharmaceuticalsEnanta Pharmaceuticals (NASDAQ:ENTA) is a biotechnology company focused on discovering and developing small-molecule therapies for viral infections and liver diseases. The company’s research and development activities have included treatments for hepatitis B virus (HBV), respiratory syncytial virus (RSV), SARS-CoV-2 and other infectious diseases. Enanta’s most notable commercial contribution is glecaprevir, a direct-acting antiviral developed in collaboration with AbbVie and included in the Mavyret and Maviret treatment for chronic hepatitis C virus (HCV) infection. Enanta also discovered paritaprevir, another HCV antiviral used in earlier AbbVie combination regimens. These products have helped establish the company’s expertise in antiviral drug discovery, although commercialization and marketing activities are conducted primarily through partners. Founded in 1995 and headquartered in Watertown, Massachusetts, Enanta conducts research and clinical development activities through its U.S. operations and collaborations with pharmaceutical companies. The company is led by Jay R. Luly, Ph.D., who serves as president and chief executive officer.View Enanta Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
